For patients with COPD, higher blood eosinophil counts, along with clinical characteristics such as smoking status, exacerbation history, and type of COPD therapy, may help identify patients more ...

Please provide your email address to receive an email when new articles are posted on . Researchers recruited 50 outpatients with physician-diagnosed and spirometry-confirmed COPD (mean age, 69 years; ...

A recent review found that factors influencing blood eosinophil stability, a potential biomarker for chronic obstructive pulmonary disease (COPD), need further research. A review published in Canadian ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab received FDA approval for treating adults with poorly controlled COPD with type 2 inflammation in ...

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...

Data from a study of smokers with chronic obstructive pulmonary disease (COPD) indicate that the concentration of eosinophils in the sputum, rather than the blood, is a better predictor of COPD ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Eosinophil Granulocytes COPD Patients with COPD who exhibit low blood eosinophil counts had no change in exacerbations or survival compared with patients with typical counts. Patients with chronic ...

Both blood eosinophil-directed treatment (BET) and standard care treatment (ST) similarly reduced treatment failure following acute exacerbations in chronic obstructive pulmonary disease (COPD). The ...

The efficacy and safety of benralizumab, an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic ...